Hyperbaric Oxygen Therapy Market size worth $ 4.79 Billion, Globally, by 2028 at 6.24% CAGR: Verified Market Research®
September 23, 2021 10:00 ET
|
Verified Market Research
Jersey City, New Jersey, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, “Hyperbaric Oxygen Therapy Market” By Product Type (Monoplace HBOT, Topical HBOT,...
Monoclonal Antibodies Market Trends 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
July 22, 2021 06:00 ET
|
Graphical Research
Pune, India, July 22, 2021 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size is poised to show tremendous growth during the forecast period owing to rise in the percentage of people...
Monoclonal Antibodies Market revenue to cross USD 380 Bn by 2027: Global Market Insights Inc.
June 08, 2021 04:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, June 08, 2021 (GLOBE NEWSWIRE) -- According to latest report “Monoclonal Antibodies Market by Type (Fully Human, Humanized, Chimeric), Application (Oncology, Autoimmune...
Immunofluorescence Assay (IFA) Market Size to Reach USD 4.01 Billion in 2028; Growing application of IFA in research and clinical diagnostics is also expected to boost demand for kits and drive revenue growth, Says Reports and Data
June 02, 2021 14:00 ET
|
Reports and Data
New York, June 02, 2021 (GLOBE NEWSWIRE) -- Growing prevalence of cancer, rapid advancements in medical and clinical infrastructure, increasing demand for quick and efficient assays, and progressing...
Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
February 22, 2021 08:30 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
January 04, 2021 08:00 ET
|
Pandion Therapeutics, Inc.
-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...
Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
December 03, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 16:01 ET
|
Pandion Therapeutics, Inc.
- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...
Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020
October 28, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit
September 24, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...